Free Trial

Aprea Therapeutics (APRE) SEC Filings & 10K Form

Aprea Therapeutics logo
$1.89 -0.04 (-2.07%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.83 -0.06 (-3.39%)
As of 07/25/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Aprea Therapeutics SEC Filings

DateFilerForm TypeView
05/14/2025
7:05 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2025
7:10 AM
Aprea Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/22/2025
3:25 PM
Aprea Therapeutics (Filer)
Form ARS
04/08/2025
2:14 PM
Aprea Therapeutics (Subject)
Sio Capital Management, LLC (Filed by)
Form SCHEDULE 13G/A
04/04/2025
6:30 AM
Aprea Therapeutics (Issuer)
Gilad Oren (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2025
3:31 PM
Aprea Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2025
7:40 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2025
7:45 AM
Aprea Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2025
11:15 AM
Aprea Therapeutics (Subject)
Stonepine Capital Management, LLC (Filed by)
Form SCHEDULE 13G/A
02/10/2025
11:56 AM
Aprea Therapeutics (Subject)
Sio Capital Management, LLC (Filed by)
Form SCHEDULE 13G/A
02/10/2025
7:36 AM
Aprea Therapeutics (Subject)
HIRSCHMAN ORIN (Filed by)
Form SCHEDULE 13G/A
02/05/2025
7:30 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
7:00 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
3:53 PM
Aprea Therapeutics (Subject)
Nantahala Capital Management, LLC (Filed by)
Form SCHEDULE 13G
11/07/2024
7:35 AM
Aprea Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/07/2024
7:38 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/25/2024
4:42 PM
Aprea Therapeutics (Issuer)
Duey Marc (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2024
7:30 AM
Aprea Therapeutics (Issuer)
Gilad Oren (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
8:00 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2024
7:30 AM
Aprea Therapeutics (Issuer)
Duey Marc (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
7:30 AM
Aprea Therapeutics (Issuer)
Hamill John P. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
7:30 AM
Aprea Therapeutics (Issuer)
Duey Marc (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
7:31 AM
Aprea Therapeutics (Issuer)
Gilad Oren (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
7:30 AM
Aprea Therapeutics (Issuer)
Hamill John P. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
7:31 AM
Aprea Therapeutics (Issuer)
Gilad Oren (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
7:31 AM
Aprea Therapeutics (Issuer)
Seizinger Bernd R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2024
7:45 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
7:35 AM
Aprea Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2024
7:40 AM
Aprea Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:APRE) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners